Like any successful business, we continue to evolve, progress, and achieve new goals. We would like to share these changes with you, so that you are always informed about the latest news.
Munich, 12th October 2022 – The European Institute of Innovation and Technology (EIT) announced the winners of the 2022 EIT Awards, the prestigious innovation prize now in its ninth year at the EIT Summit in Brussels, Belgium.
The winners of this year’s EIT Awards, which aim to promote innovation in the fields of climate, energy, digitalisation, food, health, manufacturing, raw materials and urban mobility, were announced at the EIT Summit in Brussels. Twenty-seven nominees competed in an online semi-final on 29 September, after which 12 finalists were chosen and ranked by an international jury, with an additional prize being awarded through a public vote. The 12 finalists fall into four main categories: Change Award, Innovators Award, Venture Award as well as Women Leadership Award. All awards highlight exceptional individuals supported by and involved with the EIT Community.
Catherine Schreiber, the Deputy-CEO and co-founder of ADVITOS, was ranked first in the Women Leadership Award as recognition for her entrepreneurial and social achievements. Together with Assoc.-Prof. Dr Bernhard Kreymann, ADVITOS founder and inventor of the 4-in-1 organ support therapy ADVOS, she developed the ADVOS device from scratch, launching it from an idea to an EU market-approved (CE mark) product.
Catherine Schreiber said: “Finalists Andrea Barber, Sabrina Malpede and myself have in common that we not only successfully scaled highly innovative start-ups, but also tackle societal challenges by volunteering and starting social initiatives. In my case, I have launched and financed a mental strength for founders programme consisting of mental training, professional coaching and peer support, and I advise the trauma support group for immigrant, non-German speaking women in Munich. I am truly honoured to receive this outstanding recognition. ADVITOS has highly benefited from valuable EIT support in the past, especially the EIT digital Access to Finance active fundraising support was opening doors to investors, which otherwise would have been closed.
I dedicate this price to company and ADVOS inventor Bernhard Kreymann, my strongest supporter, my closest companion and beloved best friend who sadly died from a heart attack in July 2022. Bernhard’s commitment, sense of responsibility and great humanity will always be the example I want to live up to.”
Nektarios Tavernarakis, Chair of the EIT Governing Board, said: “I want to congratulate the achievements of this year’s winners and nominees who have distinguished themselves with their transformative solutions. As Europe’s largest innovation ecosystem, the EIT’s mission is to drive innovation forward and bring together business, research and education to solve global challenges. Each of the 2022 EIT Award winners emulate this mission, and we will continue to support these and other entrepreneurs through every step of their journey, from their initial idea to a successful product or service for a brighter Europe.”
As Europe’s largest innovation ecosystem, the EIT strengthens Europe’s ability to innovate by powering solutions to pressing global challenges and by nurturing entrepreneurial talent to create sustainable growth and skilled jobs in Europe. The EIT is an EU body which is an integral part of Horizon Europe, the EU Framework Programme for Research and Innovation. The Institute supports the development of dynamic pan-European partnerships – EIT Knowledge and Innovation Communities – among leading companies, research labs and universities. Furthermore the EIT brings together over 3400 partners across more than 200 innovation hubs in Europe and beyond. It is the only innovation body with a presence in every EU state.
For more information about the EIT Awards please visit EIT Awards 2022 | European Institute of Innovation & Technology (EIT) (europa.eu)
About ADVITOS GmbH
Munich-based ADVITOS GmbH develops and markets the CE-certified and worldwide patented 4-in-1 ADVOS therapy (ADVanced Organ Support) – the first therapy for multi-organ support integrated in a single device. The ADVOS procedure improves patient survival by simultaneously supporting the three main detoxification organs of the human body: kidneys, liver, and lungs. The therapy enables the fluid-based removal of water-soluble toxins (kidney), protein-bound toxins (liver, kidney), and CO2 (lung). In addition, the ADVOS procedure enables the rapid correction of the acid-base balance through the targeted change of the blood pH. The ADVOS therapy is used in intensive care units at 20 leading hospitals in Germany and Austria. ADVITOS GmbH receives funding from the European Union’s Horizon 2020 research and innovation programme.
About the Mental Strength for Founders Programme in Memoriam Assoc.-Prof. Dr. Bernhard Kreymann
Based on her own experience, Catherine Schreiber has launched a training programme for mental and emotional resilience for founders. In cooperation with mental Coach Kim van Niekerk, Catherine designed this 8 month training programme consisting of mental training, professional coaching and peer support. The first cohort has started in October 2022; the next cohort is planned to start in February 2023. To make this programme affordable to founders, she co-financed the programme with her LaMonachia Business Woman Award money, which Catherine received in 2021.
The most beautiful memorial a person can be awarded lies in the hearts of those around him. (Albert Schweitzer)
We mourn the loss of our founder Assoc Prof Dr med Bernhard Kreymann, who was taken from life far too early at the age of 64 on
July 12, 2022.
Bernhard leaves behind an irreplaceable gap, not just as a physician, exceptional scientist, father of the award-winning ADVOS therapy for multi-organ support, but also as the caring head and soul of the company. With tireless commitment and a strong sense of responsibility, Bernhard built up the company and led it through all its ups and downs with tremendous foresight and great humanity. We miss him very much.
We are very proud to have been a part of his life’s work, and continue to press forward with full commitment to bring his life-saving ADVOS therapy to the world, thereby progressing and upholding his work in his memory.
Our sincerest condolences go out to his family and loved ones.
Catherine Schreiber, Co-Founder & close companion with the Management, Advisory Board, and staff of ADVITOS GmbH (formerly Hepa Wash GmbH)
The funeral service shall take place amongst his closest family and social circle.
In lieu of flowers and wreaths, the family asks for donations for Doctors without Borders / “Ärzte ohne Grenzen e. V.”.
IBAN: DE72 3702 0500 0009 7097 00
Intended purpose: Fuer das Leben. Bernhard Kreymann
Bank für Sozialwirtschaft
Here are some memories of our company founder and inventor of the ADVOS procedure:
We had the privilege of participating in the Scaling Impact Executive Education Programme at Católica Lisbon School of Business and Economics.
Together with ten fellow finalists of the EIB Institute’s SIT (Social Innovation Tournament) we were working on developing our scaling-up strategy. A whole week full of high-quality training, inspiring social innovations, and a great amount of food for thought.
We would like to thank the EIB Institute for this amazing opportunity and all lecturers for the extraordinary programme content – highly recommended.
For more information on the Social Innovation Tournament, visit https://institute.eib.org/social-innovation-tournament-2/
Tokyo, June 18th 2022 – JMEC Team 4 won the first prize creating a business plan for ADVITOS
The Japan Market Expansion Competition (JMEC) announced the winners of its 28th programme in an awards ceremony held at Tokyo American Club on June 8. The ceremony recognised the work of 52 participants from 24 countries.
JMEC Team 4 won the first prize with their business plan for ADVITOS, a German company that has produced the world’s first single-device, multi-organ treatment method. Martina Petkov, Head of Marketing said: “We are extremely proud of our JMEC team Palette and the great dedication with which they have developed the business plan for ADVITOS’ market entry into Japan. Very well-deserved 1st prize! The team did an amazing job in understanding the market specifics for our innovative ADVOS therapy and included recommendations that will provide a solid foundation to build upon our market entry strategy in the future. Our expectations from the programme were more than exceeded, and the quality of the research and analysis delivered is excellent.”
Team 7 was awarded second prize with a plan for one of Coca-Cola Bottlers Japan, Inc.’s new products.
Team 5 took third prize, having created a business plan for CooperSurgical Japan, a company that makes products that are designed to improve the health of women and babies.
Founded in 1993 by the Australian and New Zealand Chamber of Commerce in Japan, JMEC is a non-profit business planning skills–development training programme supported by 18 foreign chambers of commerce in Japan. Over the past 28 years, JMEC has trained more than 1,400 young business professionals, many of whom have gone on to rise in their companies or start their own businesses.
Built around a business plan competition, JMEC provides classroom training followed by hands-on experience for up-and-coming managers living and working in Japan. To date, JMEC has provided 286 business plans to help companies enter or expand in the Japanese market.
The JMEC 29 programme starts in August 2022 with information sessions for potential participants, attended by JMEC staff and alumni.
See the website for information session details: www.jmec.gr.jp
Munich, June 01st 2022 – ADVITOS GmbH appoints new CEO and reveals future plans for growth
ADVITOS GmbH is well-known for its breakthrough innovation in the medical technology on account of the unique and effective ADVOS procedure. After continuous advancements under the leadership of Assoc Prof Dr Bernhard Kreymann, the Munich-based company underwent organisational changes aiming future growth in mid-2022. On June 1, Dr Kreymann handed over his responsibility as CEO into the trusting hands of Dr Claus Jessen. Jessen’s focus will lie on the successful commercialisation of the multi-organ support therapy, while founder and developer Kreymann will remain with ADVITOS GmbH as a medical and scientific expert.
Competences used in a targeted manner
ADVITOS GmbH appoints Dr Claus Jessen as CEO of the company effective of June 1, 2022. Dr Jessen, previously acting as Head of R&D since 2021, had been involved in the work of ADVITOS GmbH since its foundation back in 2005 as an external contributor in various functions.
Today ADVITOS GmbH is evolving from a start-up to an internationally oriented medical device company. The future activities will focus on further developing the ADVOS system, increasing sales in the DACH region, strengthening the medical evidence in additional patient populations, and preparing for internationalisation.
Dr Kreymann laid the foundation of the current ADVITOS GmbH and the unique ADVOS procedure, at first on his own initiative, through tireless commitment, a high level of expertise and a keen pioneering spirit. His fundamental contribution and medical talent are highly appreciated by the entire team as well as by his CEO successor Dr Jessen and shall continue to shape the company’s path. While Dr Jessen brings 20 years of management experience in medical technology and industrial automation to the further advancement of ADVITOS GmbH, Kreymann will remain involved in the company’s activities as a scientific and medical expert as well as a member of the Advisory Board.
Economically and scientifically on the same page
Dr Kreymann will focus his core competences in the medical and scientific field on the further optimisation of the ADVOS therapy, for which Jessen now provides the necessary backing. “I look forward to leading the unique and effective therapy, that Bernhard Kreymann invented, into the market success it deserves. Together with the entire ADVITOS team, we will focus on expanding the indications of the therapy and accelerate its distribution with initial focus on the German-speaking markets,” says Dr Claus Jessen regarding his new responsibility.
The Chairman of ADVITOS’ Advisory Board, Mr Mathias Klingler, says: “On the company side, it was always clear that Dr Kreymann should remain an integral part of ADVITOS in the future. We are, therefore, very glad to have him on board as a scientific and medical expert as well as a member of the Advisory Board. The Advisory Board is very grateful to Dr Kreymann for all his dedicated work throughout the years that has significantly shaped the company’s advancement to date. We can also embark on this new chapter in the company’s history in the certainty that we can always rely on the know-how, ingenuity and technical expertise of our founder.”
Munich, 27th January 2022 – ADVITOS grows by new competences and capacities in three positions
ADVITOS enjoys a well-earned reputation in the field of medical technology on the back of its self-developed ADVOS procedure – the 4-in-1 organ support for the treatment of multi-organ failure. The special properties along with the USPs of the ADVanced Organ Support (ADVOS) have been well received by its users in the medical community. The Munich-based scale-up has particularly enjoyed a healthy growth coupled with regular personnel acquisitions within the last decade. At the transition of 2021/2022, the team of experts in the field of multi-organ support is expanding once again. With three new additions in the medical management and sales and product management, ADVITOS continues on its path to further growth.
Assoc.-Prof. Dr. Dr. Tobias Bingold has already taken up his position as Medical Director at ADVITOS in December 2021. At the beginning of 2022, the new Sales Director for the DACH region, Michael Spindeldreher, and the Product Manager, Thomas Lange, have also stepped into their roles. As of January 2022, the interdisciplinary team now comprises around 60 international specialists.
Medical Director – Important Interface and Organization of Clinical Studies
The position of the Medical Director is staffed by Assoc.-Prof. Dr. Dr. Tobias Bingold with his long-standing clinical experience, sound technical expertise and versatile competencies. The future development of ADVITOS finds invaluable assets with this key role and the expertise of Bingold.
As Medical Director, Bingold forms a crucial interface between ADVITOS and the physicians in the hospitals. The focus of his activities lies on the planning and coordination of clinical studies. With Bingold, ADVITOS has gained more than 30 years of practical experience and solution-oriented expertise.
Tobias Bingold brings Clinical Experience and Subject Matter Expertise to the Table
As a link between the company and the hospitals and physicians, Bingold is likely to benefit from various stations in his career. As Managing Senior Physician for Intensive Care Medicine at Frankfurt University Hospital and as Clinic Director of the Clinic for Interdisciplinary Intensive Care Medicine and Intermediate Care at Helios Kliniken Wiesbaden (HSK) alone, Bingold can look back on more than ten years of experience in the medical management.
The professional proximity to the core competence of ADVITOS, as well as to the field of application of the ADVOS procedure has also been provided. In addition to his various roles in anesthesiology, intensive care medicine and pain therapy, Bingold’s range of qualifications also includes a focus on infectious diseases. His multifaceted commitment is also reflected in his contribution to various medical publications, and in his membership in medical specialty societies.
New Director in DACH Sales
In the beginning of January, Michael Spindeldreher has also joined ADVITOS as Sales Director DACH. Spindeldreher takes up the sales activities entrusted to him in Germany, Austria and Switzerland not only with great experience and profound knowledge, but also out of genuine conviction and enthusiasm for the ADVOS therapy.
Spindeldreher brings more than 15 years of professional experience to his new sales role, including former positions in customer service management, product management and international sales. His most recent role was that of Director of Sales at The Surgical Company since 2017. Here he succeeded to build a field sales team, and help the company become a market leader. Spindeldreher had already been eyeing the ADVITOS developmental endeavours with interest since 2019. He is convinced of the trend-setting idea, the innovative power, and effectiveness of the ADVOS therapy, and would like to actively contribute to its commercialization using his expertise from now on.
Additional personnel also in sales, marketing, and product positioning
The position of the new product manager has been filled by Thomas Lange since the beginning of January. With almost 30 years of practical experience and distinct competence in the field of medical technology, Lange’s ambition is to significantly expand the market share of the ADVOS therapy. Core competencies in sales and product management make Lange the ideal candidate for his position at ADVITOS, where he will be responsible for market-specific sales strategies, product-specific marketing plans and product positioning, amongst other things.
This latest staff expansion by three established experts is a further sign of the determined course of ambition-fueled growth of ADVITOS. In 2022 and in the subsequent future, the company is looking forward to decisive developments in the market for medical products, which it intends to meet with motivation and drive, with expanded capacities and a high level of confidence. Tobias Bingold, Michael Spindeldreher, and Thomas Lange are convinced of the potential and effectiveness of the ADVOS therapy. As specialists experienced in medical technology, they are looking forward to making a sustainable contribution to its development and establishment.
On 7 October, we are one of the 15 finalists taking the stage in Lisbon to pitch our project for a chance to win one of the many prizes of the Social Innovation Tournament (SIT)!
The SIT is a European Investment Bank Institute competition that rewards European entrepreneurs aiming to generate social or environmental impact with projects implemented in Europe.
Audience can vote for three favourite projects.
Register now to attend the Final in Lisbon on 7 October or watch the livestreaming www.sit2021.org
Munich, 11th August 2021 – New blood purification procedure ADVOS rapidly normalizes acid-base imbalance, a major contributor to mortality in COVID-19 patients
Impaired oxygenation is the most common clinical presentation in COVID-19 patients, however, some of them also develop problems with carbon dioxide removal. This contributes to acid-base imbalance, one of the strongest risk factors for critically ill patients.
ADVOS procedure supports main organs of acid-base balance
The mortality rate of COVID-19 patients with multi-organ failure is high, especially when the main detoxification organs of liver, lung and kidney have limited function. These three organs are also the main organs to maintain acid-base balance in the physiological range.
The ADVOS (ADVanced Organ Support) procedure takes a new approach. It is the world’s first blood purification procedure for combined multi-organ support of the liver, lungs, kidneys, and acid-base balance – in other words, a 4-in-1 therapy. Through the direct acid removal of the ADVOS procedure, all three organs can be directly supported for the normalization of the acid-base balance.
Study shows therapy success
In a new study conducted by the II Medical Clinic of the Klinikum rechts der Isar of the Technical University of Munich, the focus was on the ability of the ADVOS procedure to support the role of the lungs in acid-base balance. The aim of the study was to evaluate the ADVOS system as a treatment option in predominantly elderly COVID-19 patients with multiple organ failure and problems with carbon dioxide removal.
For the patients in the study, rapid correction of acid-base balance and continuous carbon dioxide removal were achieved during ADVOS treatments. In addition, a significant normalization of blood pH was realized after the first ADVOS treatment.
Over the treatment period, it was thus possible to rapidly normalize one of the strongest risk factors for increased mortality in COVID-19 patients with acute respiratory distress syndrome and multiple organ failure.
The study thus demonstrates that the ADVOS therapy can positively impact the treatment of critically ill COVID-19 patients.
If you would like to read the entire study, please visit Extracorporeal carbon dioxide Removal (ECCO2R) with the Advanced Organ Support (ADVOS) system in critically ill COVID‐19 patients – Allescher – – Artificial Organs – Wiley Online Library
Munich, 13th July 2021 – The city of Munich has awarded the “LaMonachia” prize for the third time. The business award for women honors successful female managers and entrepreneurs from Munich.
Due to the pandemic, the award ceremony had to be cancelled last year, so in 2021 four instead of two award winners were honored. Mayor Katrin Habenschaden presented the award to the female entrepreneurs: “I am very pleased about the many applicants and thank them on behalf of the city of Munich. With their business ideas, their innovative strength and above all their tireless entrepreneurial commitment, they enrich Munich as a business location. As economically successful women, they are important role models.”
One of this year’s award winners is Catherine Schreiber, Deputy Managing Director of ADVITOS GmbH. Together with company founder PD Dr. Bernhard Kreymann and her team, the engineering graduate has launched the world’s only 4-in-1 organ support therapy, which supports the liver, lungs and kidneys as well as corrects the acid-base balance.
“What a great honor and pleasure to be among the four 2021 awardees and to receive this award. I also owe this award to the great ADVITOS team and company founder Bernhard Kreymann – together we create something truly unique and overcome every challenge.”
The winners also include Rosie Schuster, founder and CEO of Techcast GmbH, Yao Wen, co-founder and CEO CIP Group and Katja Zukic, managing partner of Gustav van Treeck Werkstätten für Mosaik und Glasmalerei GmbH.
The jury, which included representatives from Munich’s city council, business community and chambers of commerce, selected the winners from 56 applications. The decision criteria were economic success, innovation, and commitment. Clemens Baumgärtner, Head of the Department of Labor and Economics: “The candidates were all inspiring and successful, whether in their own companies or as employed managers. They create jobs in predominantly medium-sized companies and a wide variety of industries. Munich has women power and we are proud to be able to show that with LaMonachia.”
LaMonachia is the Latin name and allegory of the female Munich, which is depicted in two large paintings in Munich City Hall. The symbol for the LaMonachia business award is the lioness – an international symbol of strength, serenity, and natural authority.
Department of Labor and Economics, 13.07.2021 La Monachia Award
Ceremony at the Deutsches Theater Photo: Marion Vogel
Munich / Paris / Frankfurt am Main, June 10, 2021
ADVITOS GmbH (“ADVITOS”), a Munich-based medical technology company, today announced the completion of a EUR 20 million financing round. The financing round was led by Crédit Mutuel Equity via its two subsidiaries Crédit Mutuel Equity Germany and Crédit Mutuel Innovation. In addition, ADVITOS received funding from the European Union’s European Innovation Council (EIC) Fund as part of the EIC Accelerator Pilot blended finance program.
ADVITOS developed and markets the ADVOS multi-device (ADVanced Organ Support) to provide an integrated 4-in-1 multi-organ support therapy that enables simultaneous support of all three main detoxification organs – liver, lungs and kidney – and corrects blood acid-base imbalances. Pilot trials in critically ill patients have shown that this therapy increased survival in severe organ failure from 20% up to 50%.
Multi-organ failure causes the deaths of approximately half a million intensive care patients in Western Europe and the USA every year. This is about 60 percent of all deaths in intensive care units. Due to the Covid-19 pandemic, this number has increased to around 750,000 patients in the past year. On the other hand, conventional extracorporeal procedures such as mechanical ventilation, ECMO (extracorporeal membrane oxygenation), dialysis and liver-assist therapy only support the function of one or two organs. By treating all three organs simultaneously, and not consecutively like with existing solutions, it is a holistic approach giving the patients a much better chance to recover. The ADVOS therapy is CE marked, recognized by international experts, and is already in use in the intensive care units of over 20 hospitals throughout Germany, including a number of leading university hospitals.
ADVITOS developed key proprietary components of the ADVOS therapy and the ADVOS multi-device on its own and holds several patents related to technology and process features. With the current financing round, the company intends to further increase medical evidence through clinical trials, expand its commercialization internationally and to add additional therapy features to increase ease of use of the ADVOS multi.
ADVITOS was founded in 2005 by nephrologist Bernhard Kreymann, M.D., who is also the inventor of the ADVOS therapy. ADVITOS began as a start-up in a research laboratory in Garching near Munich. Catherine Schreiber complemented Bernhard Kreymann with her business and engineering background. Together they developed ADVITOS over the years with the help of several financing rounds with the participation of private investors, the KfW banking group and employees. The company presently employs 55 people. It has received numerous awards, including the 2020 Innovation Award Bavaria, and is listed in the Deloitte Technology Fast 50 Awards 2019.
Bernhard Kreymann, founder and CEO of ADVITOS, said: “This financing round is a major step in the further development of ADVITOS. It will enable us to grow much faster in the future and to embark on several major development projects in both research & development and sales & marketing. Together with our new financing partners, we are also gaining an incredibly diverse set of competencies and expertise to support these projects and open new doors for ADVITOS.”
Delphine Cardi, PhD, Investment Director at Crédit Mutuel Innovation in Paris, added: “With this round of financing, we are extremely pleased to support not only an economically promising company but above all to improve the medical care of critically ill patients.”
Sébastien Neiss, Managing Director of Crédit Mutuel Equity in Germany, further comments: “It was important to us to make a sustainable contribution to the future of the company and its mission. To this end, ADVITOS not only receives venture capital from our colleagues at Crédit Mutuel Innovation in France, the EIC Fund and other co-investors. Through the participation of Crédit Mutuel Equity, we will also support the international development of ADVITOS by making available long-term growth capital that is not dependent on predefined time horizons. This will enable us to adapt to the growth dynamics of the company and, if required, enables us to reinvest in case of changes in the shareholder structure or future growth projects.”
Laura González-Estéfani, EIC Fund Investment Committee member, said: “We are delighted to announce that the EIC Fund is supporting ADVITOS in this successful financial round. This allows this highly innovative company to further develop their product and bring it closer to the market”.
Mathias Klingler, chairman of the supervisory board of ADVITOS and authorized representative of the main private investor, sees the financing round as a great opportunity to use the unique therapy from ADVITOS internationally for the further benefit of patients and thus save lives.
About Crédit Mutuel Equity
Crédit Mutuel Equity (formerly CIC Capital) is the private equity subsidiary of Crédit Mutuel Alliance Fédérale and carries out venture capital, growth capital and buyout activities.
Crédit Mutuel Equity supports business leaders at all stages of their companies’ development, from seed phase to buyout, by providing them with the means and the time required to implement their transformational projects. Crédit Mutuel Equity brings together a network of over 350 business leaders and entrepreneurs who share similar convictions and can benefit from one another’s experience, no matter the nature of their projects. Using its own funds (€3.0 billion), Crédit Mutuel Equity makes investments tailored to the time horizons and growth strategies of the companies in which it invests, whether in France, Canada, the United States, Germany or Switzerland.
For more information, see www.creditmutuel-equity.eu
About Crédit Mutuel Innovation
Crédit Mutuel Innovation is the venture capital subsidiary of Crédit Mutuel Equity. Its objective is to invest in companies developing promising technologies. Crédit Mutuel Innovation selects companies with strong growth potential in dynamic sectors such as information technology, telecommunications, electronics, life sciences, new materials and environment. For more than 15 years, Crédit Mutuel Innovation has invested – and often reinvested – its own capital to support innovative companies all along their development. Crédit Mutuel Innovation’s policy is to provide long-term equity support to innovative startups to streamline their chances of success.
For more information, see www.creditmutuel-equity.eu
About Crédit Mutuel Alliance Fédérale
One of France’s leading bank insurers, operating through nearly 4,300 branches serving 26.7 million customers, Crédit Mutuel Alliance Fédérale offers a diversified range of services to a wide range of customers, from private individuals and local professionals to businesses of all sizes.
One of Europe’s strongest banking groups, its shareholders’ equity amounted to €49.6 billion and its CET1 ratio was 17.8% at 30 December 2020.
Crédit Mutuel Alliance Fédérale is made up of the following Crédit Mutuel federations: Centre Est Europe (Strasbourg), Sud-Est (Lyon), Ile-de-France (Paris), Savoie-Mont Blanc (Annecy), Midi-Atlantique (Toulouse), Loire-Atlantique et Centre-Ouest (Nantes), Centre (Orléans), Normandie (Caen), Dauphiné-Vivarais (Valence), Méditerranéen (Marseille), Anjou (Angers), Massif Central (Clermont-Ferrand) and Antilles-Guyane (Fort-de-France).
Crédit Mutuel Alliance Fédérale also encompasses Caisse Fédérale de Crédit Mutuel, Banque Fédérative du Crédit Mutuel (BFCM) and all its subsidiaries, including CIC, Euro-Information, Assurances du Crédit Mutuel (ACM), Targobank, Cofidis Group, Banque Européenne du Crédit Mutuel (BECM), Banque de Luxembourg, Banque Transatlantique and Homiris.
For more information, see www.creditmutuelalliancefederale.fr
About the European Innovation Council Fund
Established in June 2020, the European Innovation Council Fund (EIC Fund) is a breakthrough initiative of the European Commission to make direct equity and quasi-equity investments (between €500.000 and €15 million) in European high impact and deep tech start-ups and scale ups. The EIC Fund provides patient capital and invests in companies from any sector, across all EU countries and countries associated to Horizon 2020.
The Fund pays particular attention to empower and support female founders as well as contributing to reduce the innovation divide among EU countries.
The EIC Fund aims to fill a critical financing gap and its main purpose is not to maximize financial investment returns, but to have a high impact by accompanying companies with and disruptive technologies in their growth. Its objective is to crowd in market players, further sharing risks by building a large network of capital providers and strategic partners suitable for co-investments and follow on funding.
About EIT Digital Accelerator
EIT Digital Accelerator supports international growth of European digital tech scaleups by helping them raise venture capital and access new markets. Since 2012, EIT Digital Accelerator’s team of venture financing and business experts has been working with 300+ companies across Europe who collectively raised over €1 billion in investment.
ADVITOS developed the CE-marked and globally patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi-organ support integrated in one single device. The ADVOS therapy improves survival of ICU patients by simultaneously supporting all three main detoxification organs: the liver, the lung, and the kidney. The solution allows fluid-based elimination of: water-soluble toxins (kidney), protein-bound toxins (liver and kidney), and CO2 (lungs). In addition, the ADVOS therapy enables treatment of acid-base disbalances through patient-individual correction of the blood pH value. The ADVOS therapy is used in intensive care units at 20 leading hospitals throughout Germany and is on its way to entering the international market. ADVITOS receives funding from the European Union’s Horizon 2020 research and innovation programme.
Participants in the transaction
Finance & Tax-Advisory: Eight Advisory (Marc Niclas, Jan-Ole Burchert, Manuel Wahl)
EIT Digital Accelerator (Daniel Michel)
Legal: Goodwin Procter LLP (Gregor Klenk, Joana Pamukova), Implid Legal (Benoît Lespinasse)
Heussen Rechtsanwaltgesellschaft mnH (Cornelia Weber; Gerhard Pischel), Field Fischer (Andreas Driver),
CMS (Henrik Drinkuth; Arian Nazari-Khanachayi, Frederike Volkmann), Oppenhoff (Johannes Janning)
IP: Franck Tetaz Intellectual Property, Graf von Stosch Patentanwaltsgesellschaft mbH
Tel. +49 (0) 170 45 83 38 3 // +49 (0) 89 4111842-27
Credit Mutuel Equity – Credit Mutuel Innovation
Georg Schattney/Jan P. Sefrin
Tel. +49 (0)69 79 40 90-44/26